Market Overview

Biotech Winners And Losers From Congress' Latest Funding Bill

Biotech Winners And Losers From Congress' Latest Funding Bill
Related NVS
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall
Cancer Research Highlight: Blueprint Medicines Lets Loose In GIST (Seeking Alpha)
Related PFE
October's biggest Losers And Most Surprising Winners
Tariffs, Drug Prices, Legislative Gridlock: What Economists Are Watching Following The Midterm Election
SoftBank Puts Another $3B In WeWork (Seeking Alpha)

Congress introduced the Consolidated Appropriations Act of 2018 on Wednesday, and the bill contains fewer health care provisions than many traders expected.

Still, Height Capital Markets analyst Andrea Harris said on Thursday there are several pharmaceuticals and managed care winners and losers from the new bill.


Among the biggest winners is Omeros Corporation (NASDAQ: OMER).

“Title XIII, which begins on page 2028 of the Consolidated Appropriations Act, is a narrowly designed provision that extends by two years the pass-through status period for qualifying drugs, including OMER's Omidria,” Harris said.

Novartis AG (ADR) (NYSE: NVS) and Pfizer Inc. (NYSE: PFE) will continue to benefit from the status quo, but the same can't be said for a couple of other big names.


Amgen, Inc. (NASDAQ: AMGN) and Johnson & Johnson (NYSE: JNJ) investors are likely disappointed the new bill doesn’t include provisions both companies had been pushing for.

“The Consolidated Appropriations Act does not include a separate pass-through-related provision advocated by Amgen and Johnson & Johnson (JNJ) that would have reversed a reimbursement disadvantage that resulted from the 340B payment cuts in the 2018 outpatient prospective payment system (OPPS) rule,” Harris said.

“This policy, which would have applied 340B reimbursement cuts to drugs with pass-through status (they are currently exempt from the cuts) originally surfaced in the House-passed spending bill in February (the Senate version, which became law, did not include the change)."

Congress didn't scale back the required drug discounts sold in the Medicare Part D coverage gap, meaning manufacturers are still on the hook for providing 70 percent discounts starting in 2019.

Related Links:

Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud'

Akcea Therapeutics Downgraded By Wells Fargo After Huge Run

Latest Ratings for NVS

Sep 2018CitigroupUpgradesNeutralBuy
Sep 2018Bank of AmericaUpgradesUnderperformBuy
Jul 2018BarclaysUpgradesUnderweightEqual-Weight

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Andrea HarrisAnalyst Color Health Care Politics Top Stories Analyst Ratings Trading Ideas General Best of Benzinga


Related Articles (AMGN + JNJ)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Buy Hasbro As Toys 'R' Us Liquidates, Says KeyBanc Analyst

Will Starbucks Benefit From Digital Platform Expansion?